Deulorlatinib(TGRX-326)在ALK阳性非小细胞肺癌中的安全性、疗效及生物标志物分析:一项多中心、开放标签、1/1b期试验
这项在中国22家中心开展的1/1b期试验评估了Deulorlatinib在ALK阳性非小细胞肺癌中的安全性、疗效和药代动力学,共纳入198例患者(ALK阳性171例,ROS1阳性27例)。最常见的治疗相关不良事件为高胆固醇血症(79.3%)、高甘油三酯血症(77.3%)和体重增加(53.0%),40.4%的患者发生≥3级治疗相关不良事件。在推荐2期剂量60 mg每日一次下,克唑替尼经治、二代TKI经治和TKI初治患者的客观缓解率分别为71.4%、38.1%和87.9%。
要点
- Deulorlatinib推荐2期剂量为60 mg每日一次。
- 二代TKI经治患者客观缓解率38.1%,颅内客观缓解率70.4%。
- 基线检测不到ALK变异和6周时ALK循环肿瘤DNA清除为潜在预测生物标志物。
核心结论
- Deulorlatinib在ALK阳性非小细胞肺癌中表现出可接受的耐受性和疗效,有望成为该人群的新治疗选择。
研究设计与样本
- 这是一项在中国22家中心开展的三部分(剂量递增/剂量扩展/队列扩展)、开放标签、1/1b期试验(ClinicalTrials.gov,NCT05441956)。
- 纳入晚期ALK/ROS1阳性非小细胞肺癌患者,剂量递增/扩展部分患者既往接受过一种或以上二代ALK抑制剂(ALK阳性)或克唑替尼(ROS1阳性),队列扩展部分患者为克唑替尼经治、二代TKI经治或TKI初治。
- 共纳入198例患者(ALK阳性171例,ROS1阳性27例),入组时间为2021年4月至2023年3月。
- 主要结局为安全性和耐受性,本文报告所有患者的安全性分析和ALK阳性患者的疗效分析。
主要发现
- 最常见治疗相关不良事件为高胆固醇血症(79.3%)、高甘油三酯血症(77.3%)和体重增加(53.0%)。
- 40.4%的患者发生≥3级治疗相关不良事件。
- 治疗相关不良事件导致剂量中断、减量和停药的患者比例分别为11.1%、3.0%和1.5%。
- 在推荐2期剂量60 mg每日一次下,克唑替尼经治(n=14)、二代TKI经治(n=97)和TKI初治(n=33)患者的客观缓解率分别为71.4%、38.1%和87.9%。
- 颅内客观缓解率分别为50%、70.4%和75%;二代TKI经治患者中位缓解持续时间为18.0个月,克唑替尼经治和TKI初治患者未达到。
关键数值与推荐
- 推荐2期剂量设定为60 mg每日一次。
- 生物标志物分析发现基线检测不到ALK变异和6周时ALK循环肿瘤DNA清除为潜在预测生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Patients with anaplastic lymphoma kinase (ALK)-positive NSCLC developing resistance to second-generation inhibitors have limited treatment options. Deulorlatinib is a highly brain-penetrant, new-generation ALK/ROS1 inhibitor. We evaluated the safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC. METHODS: This three-part (dose-escalation/dose-expansion/cohort-expansion), open-label, phase 1/1b trial was conducted at 22 sites in the People's Republic of China (ClinicalTrials.gov, NCT05441956). Patients who were eligible had advanced ALK/ROS1-positive NSCLC. Patients enrolled in dose-escalation/dose-expansion parts were previously treated with one or more second-generation ALK inhibitors (ALK-positive) or crizotinib (ROS1-positive) and received deulorlatinib 5 to 125 mg once per day. Patients enrolled in cohort-expansion parts were either crizotinib-treated, second-generation tyrosine kinase inhibitor (TKI)-treated, or TKI-naïve; and received deulorlatinib at the recommended phase 2 dose (RP2D). The primary outcomes were safety and tolerability. Here, we report safety analysis in all patients and efficacy analysis in patients who were ALK-positive. RESULTS: Between April 2021 and March 2023, 198 patients were enrolled (ALK-positive = 171, ROS1-positive = 27). The most common treatment-related adverse events (TRAEs) were hypercholesterolemia (79.3%), hypertriglyceridemia (77.3%), and weight gain (53.0%). 40.4% of patients had grade 3 or higher TRAEs. Meanwhile, TRAE-associated dose interruptions, reduction, and discontinuation occurred in 11.1%, 3.0%, and 1.5% of patients, respectively. The RP2D was set at 60 mg once per day. A total of 144 patients who were ALK-positive were treated at RP2D. For crizotinib-treated (n = 14), second-generation TKI-treated (n = 97), and TKI-naïve (n = 33) patients, the objective response rate to deulorlatinib at RP2D was 71.4%, 38.1%, and 87.9%, respectively. Intracranial objective response rate was 50%, 70.4%, and 75%, respectively. The median duration of response was 18.0 months for second-generation TKI-treated patients, and not reached for patients who were crizotinib-treated and TKI-naïve. Biomarker analyses identified undetectable ALK alterations at baseline and ALK circulating tumor DNA clearance at week 6 as potential predictive biomarkers. CONCLUSIONS: Deulorlatinib reported desirable tolerability and efficacy in ALK-positive NSCLC, demonstrating the potential to become a new treatment option in this population.
引用
- Zhao S, Zhou H, Yang N, et al. Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial. J Thorac Oncol. 2024. PMID: 39551469. doi:10.1016/j.jtho.2024.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。